Evaluation of Aficamten in Patients with Symptomatic Non-obstructive Hypertrophic Cardiomyopathy: REDWOOD HCM Cohort 4
Long-Term Efficacy and Safety of Aficamten in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy
Aficamten in Patients with Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (REDWOOD-HCM Cohort 4)
Omecamtiv Mecarbil in Black Patients With Heart Failure and Reduced Ejection Fraction: Insights From GALACTIC-HF
Efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide level: Insights from the GALACTIC-HF trial
Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy
ENCALS Predictive Survival Model in FORTITUDE-ALS
Sex Differences in Heart Failure with Reduced Ejection Fraction in the GALACTIC-HF Trial
Improvement in KCCQ Scores in Patients with Obstructive Hypertrophic Cardiomyopathy Treated with Aficamten in the REDWOOD HCM OLE Study
